The Life Sciences team advised Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) on its initial public offering that raised approximately $231.3 million through the sale of approximately 12.2 million shares at $19 per share.
Black Diamond is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. The company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.
The Goodwin team was led by Robert Puopolo and included Mitch Bloom, Marishka DeToy and Karin Yoo.
For more details, read the press release and articles in Xconomy, Endpoints and MarketWatch,